Seraph 100 use for covid-19 under emergency use authorization (eua): diagnosed with covid-19 and acute hypoxic respiratory failure with a history of esrd on hd.She was admitted on (b)(6) 2021 and started with initial hd on (b)(6) 2021.After worsening respiratory failure noted, she was thought to be a candidate for seraph 100 use on (b)(6) 2021.Patient was started on hd with addition of hemofiltration device seraph 100 on (b)(6) 2021.She was also anticoagulated with a heparin drip per eua protocol but developed significant bleeding at av fistula site requiring blood transfusion and protamine sulfate use.She had a second round of seraph 100 on (b)(6) 2021 without complication.She developed worsening respiratory failure which required mechanical ventilation on (b)(6) 2021.She developed worsening shock with suspicion of mesenteric ischemia and bowel infarction.She developed cardiac arrest with cpr but expired on (b)(6) 2021.Fda safety report id#: (b)(4).
|